证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2021-002 | --- | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2021-003 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2021-004 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

门 昌红 科 技 证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | |-----------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------- ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2022-007 | --- | --- | --- | |---------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's revenue for Q3 2022 was CNY 337,552,437.46, representing a year-over-year increase of 7.36%[6] - Net profit attributable to shareholders for Q3 2022 was CNY 48,578,007.72, up 29.54% compared to the same period last year[6] - The net profit excluding non-recurring gains and losses for Q3 2022 was CNY 49,456,703.28, an increase of 79.47% year-over-year[6] - The basic earnings per share for Q3 2022 was CNY 0.10, a 25.00% increase compared to the same period last year[6] - Total operating revenue for the third quarter reached CNY 906,161,884.90, an increase of 4.3% compared to CNY 863,415,527.20 in the same period last year[35] - Net profit attributable to shareholders of the parent company was CNY 118,810,136.44, up 30.0% from CNY 91,394,382.88 year-on-year[39] - Operating profit for the period was CNY 138,928,849.14, representing a 26.6% increase from CNY 109,703,832.05 in the prior year[39] - Basic and diluted earnings per share were both CNY 0.24, an increase from CNY 0.20 in the same quarter last year[39] - The total comprehensive income for the period was CNY 146,207,532.00, compared to CNY 93,257,432.82 in the previous year, reflecting a significant increase of 56.7%[39] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,162,727,969.32, reflecting a 13.44% increase from the end of the previous year[6] - The total assets as of September 30, 2022, amounted to 2.163 billion CNY, an increase from 1.907 billion CNY at the beginning of the year[28] - The total liabilities as of September 30, 2022, were approximately 900.00 million CNY, up from 708.04 million CNY at the beginning of the year[31] - The company’s non-current assets totaled approximately 996.51 million CNY, an increase from 777.81 million CNY at the beginning of the year[31] - The company’s equity increased slightly, with the share capital at approximately 502.51 million CNY as of September 30, 2022[31] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 77,444,706.05, showing a significant increase of 132.82% year-over-year[6] - Cash flow from operating activities was CNY 852,445,566.05, an increase from CNY 822,733,114.82 in the same quarter last year[40] - Net cash flow from operating activities was $77,444,706.05, an increase from $33,263,606.40 in the previous period[43] - Total cash inflow from investment activities was $514,810,145.60, down from $801,801,839.31 year-over-year[43] - Cash outflow from investment activities totaled $801,204,053.21, compared to $929,083,499.69 in the previous period[43] - Net cash flow from financing activities was $76,216,609.31, a decrease from $333,592,013.19 year-over-year[43] - The net increase in cash and cash equivalents was -$122,442,174.68, contrasting with a positive increase of $238,016,968.23 in the previous period[43] - Cash and cash equivalents at the end of the period stood at $414,182,943.60, compared to $403,295,839.72 at the end of the previous period[43] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,295, with the largest shareholder, Li Huanchang, holding 40.21% of shares, equating to 202,065,500 shares[16] - Li Huanchang has 158,996,625 shares under lock-up conditions, representing 75% of his holdings as a senior executive[20] - The top ten shareholders collectively hold 202,328,000 shares, which is approximately 40.26% of the company's total equity[19] - The company has a total of 184,487,713 shares under lock-up conditions, with no new shares added during the reporting period[23] - The shareholder Zhuhai Abama Asset Management holds 9,930,000 shares, representing 1.98% of the total shares[16] - The overall shareholder structure remains stable, with no significant changes in the percentage of shares held by major shareholders[19] Strategic Developments - The company has not reported any new strategies or significant market expansions during this quarter[22] - There are no new product launches or technological advancements mentioned in the current report[22] - The company has not disclosed any mergers or acquisitions in the recent quarter[22] - The company continues to focus on maintaining its current shareholder structure without any major changes in the top ten shareholders[19] Employee Stock Ownership Plan (ESOP) - The employee stock ownership plan (ESOP) allows the purchase of up to 5.909 million shares at a revised price of 10.00 CNY per share, down from 12.00 CNY per share[24] - The first unlock condition for the ESOP now requires a net profit growth rate of at least 50.00% for 2022, reduced from 70.00%[24] - The second unlock condition for the ESOP now requires a net profit growth rate of at least 95.00% for 2023, reduced from 121.00%[24] Research and Development - Research and development expenses amounted to CNY 33,793,319.61, slightly up from CNY 33,575,975.43, indicating continued investment in innovation[35]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[25]. - The company's operating revenue for the reporting period was ¥568,609,447.44, representing a 3.57% increase compared to ¥548,994,172.87 in the same period last year[33]. - The net profit attributable to shareholders was ¥70,232,128.72, a 30.32% increase from ¥53,893,803.62 year-on-year[33]. - The net cash flow from operating activities reached ¥85,015,491.41, showing a significant increase of 247.74% compared to ¥24,447,981.13 in the previous year[33]. - The basic earnings per share increased to ¥0.14, up 16.67% from ¥0.12 in the same period last year[33]. - The gross profit margin improved to 30%, up from 28% in the same period last year[25]. - The gross profit margin for the medical devices and consumables business was 38.18%, a decrease of 5.77% compared to the previous year[72]. - The company reported non-recurring gains of ¥9,988,658.90 during the reporting period, primarily from government subsidies and asset disposals[36]. - The weighted average return on net assets was 5.95%, an increase from 5.12% in the previous year[33]. Market Expansion and Strategy - User data showed an increase in active users by 20% compared to the previous year, reaching 1 million active users[25]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2023[25]. - A strategic acquisition of a local competitor is expected to be finalized by Q4 2022, enhancing the company's product offerings[25]. - The company continues to provide one-stop services in the medical device and polymer consumables sectors, focusing on precision molds and product production solutions[42]. - The company has established a "one-stop" service capability in the medical device and reagent product supply sector, enhancing its market position through customized automation production processes and rapid after-sales service mechanisms[63]. - The company operates production bases in Shenzhen, Heyuan, Shanghai, Vietnam, and the Philippines, focusing on customer demand-driven production models[58]. - The company has 17 subsidiaries in China and 4 overseas subsidiaries located in Vietnam, the Philippines, Seychelles, and Hong Kong, indicating a robust market expansion strategy[63]. Research and Development - The company plans to invest RMB 100 million in R&D for new product development in the next fiscal year[25]. - The company has a strong emphasis on R&D, with established research centers in Guangdong and Shanghai, focusing on precision molds and medical consumables[66]. - The company emphasizes continuous investment in product and technology R&D to maintain industry leadership and mitigate risks associated with new product acceptance[102]. - The company has developed a comprehensive innovation platform that integrates technology development, product R&D, testing, and talent training[66]. Financial Management and Investments - The total amount of funds raised was RMB 460 million, with a net amount of RMB 447.74 million after deducting issuance costs[80]. - As of June 30, 2022, a total of RMB 247.39 million has been invested from the raised funds, primarily for the expansion of high-end medical equipment and consumables production lines[81]. - The project for the expansion of high-end medical equipment and consumables production lines has a total committed investment of RMB 325 million, with an investment progress of 38.35% as of the reporting date[84]. - The company has established a strict approval process for the use of raised funds to ensure they are used for their intended purposes[84]. - The company has not encountered any significant violations in the management and disclosure of raised funds[80]. - The company has a total of 51,852,410 CNY in entrusted financial management, with 35,362,410 CNY remaining unexpired[92]. - The company reported no overdue amounts in its entrusted financial management activities[92]. Risk Management - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[6]. - The company is closely monitoring exchange rate fluctuations and may engage in forward foreign exchange transactions to mitigate risks[107]. - The company faces risks related to the verification and acceptance progress of new project orders, which may not meet expectations due to client internal processes[109]. - The company has established a comprehensive intellectual property management system and signed confidentiality agreements with key technical personnel to protect core technologies[103]. Corporate Governance and Compliance - The company has established a comprehensive corporate governance structure and internal control system to protect the rights of shareholders and creditors, ensuring fair and transparent information disclosure[124]. - The company has maintained a stable financial condition with no instances of major shareholder or related party fund occupation, and no external guarantee matters[124]. - The company emphasizes employee rights protection by adhering to the Labor Contract Law and implementing a reasonable compensation management system based on various factors[126]. - The company prioritizes environmental protection and sustainable development, actively managing waste and emissions in compliance with relevant regulations[128]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[137]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 22,905, with major shareholders holding 5% or more of the shares[177]. - Li Huanchang holds 40.84% of the shares, totaling 205,245,500 shares, with a decrease of 6,750,000 shares during the reporting period[177]. - The total number of restricted shares at the end of the period was 184,480,213 shares, with 1,825 shares added during the reporting period[176]. - The company has a repurchase account holding 5,909,000 shares, accounting for 1.87% of the total share capital, intended for equity incentive plans or employee stock ownership plans[180]. - The largest shareholder group, including Li Huanchang and his concerted actors, holds a total of 205,508,000 shares, representing 40.90% of the total share capital[180]. - The company has implemented a 75% lock-up period for shares held by executives during their tenure[176]. - The total number of shares held by the top ten unrestricted shareholders includes 46,248,875 shares held by Li Huanchang[182].

Financial Performance - The company's operating revenue for Q1 2022 was ¥293,485,351.69, representing a 7.31% increase compared to ¥273,494,647.13 in the same period last year[4] - Net profit attributable to shareholders was ¥44,989,213.39, up 13.73% from ¥39,558,308.51 year-on-year[4] - The net profit after deducting non-recurring gains and losses decreased by 8.00% to ¥33,647,218.62 from ¥36,572,204.92 in the previous year[4] - Basic and diluted earnings per share rose by 25.38% to ¥0.1003 from ¥0.0800 year-on-year[4] - Total operating revenue for the first quarter was CNY 293,485,351.69, an increase of 7.3% compared to CNY 273,494,647.13 in the previous year[26] - Net profit for the period reached CNY 47,423,639.84, compared to CNY 40,898,510.69, representing a growth of 15.5%[29] - The total comprehensive income attributable to the parent company's owners was CNY 41,241,495.07, an increase from CNY 40,767,349.21 in the previous period, reflecting a growth of approximately 1.16%[32] Cash Flow and Liquidity - The net cash flow from operating activities increased by 10.16% to ¥45,957,387.87 compared to ¥41,719,444.69 in the same period last year[4] - The net cash flow from operating activities was CNY 45,957,387.87, compared to CNY 41,719,444.69 in the previous period, indicating an increase of about 10.4%[36] - The total cash inflow from operating activities was CNY 326,500,059.71, slightly down from CNY 329,499,239.99 in the previous period[36] - The cash outflow for purchasing goods and services was CNY 177,008,029.45, up from CNY 174,240,415.49 in the previous period, showing an increase of approximately 1.01%[36] - The net cash flow from investing activities was negative at CNY -138,705,890.33, a significant decrease from CNY 36,265,294.21 in the previous period[36] - The cash and cash equivalents at the end of the period were CNY 461,391,501.20, down from CNY 228,839,592.49 in the previous period[36] - The net increase in cash and cash equivalents was CNY -55,233,617.08, contrasting with an increase of CNY 63,443,701.68 in the previous period[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,985,944,709.55, a 4.16% increase from ¥1,906,571,742.00 at the end of the previous year[4] - The total liabilities increased to CNY 747,779,506.84 from CNY 708,044,226.65, reflecting a rise of 5.6%[25] - Non-current assets totaled CNY 831,439,702.12, up from CNY 777,810,718.94, indicating a growth of 6.9%[25] - The company's cash and cash equivalents as of March 31, 2022, amount to ¥489,391,573.06, down from ¥544,625,196.77 at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,617[11] - Li Huanchang holds 42.19% of the shares, totaling 211,995,500 shares, with 27,000,000 shares pledged[11] - The top ten shareholders collectively hold 42.24% of the total share capital[11] - The company has a total of 184,480,213 shares under lock-up agreements, with specific conditions for release[15] Expenses and Cost Management - Total operating costs amounted to CNY 252,600,677.61, up from CNY 228,115,875.68, reflecting an increase of 10.7%[29] - Research and development expenses for the quarter were CNY 9,992,826.93, slightly down from CNY 10,980,222.66, indicating a focus on cost management[29] - The company reported a decrease in sales expenses to CNY 11,029,821.13 from CNY 14,477,754.06, showing improved efficiency in sales operations[29] Other Income and Financial Changes - The company's financial expenses surged by 29,256.74% to ¥482.34 due to interest accrued on convertible bonds issued[10] - Other income increased by 257.27% to ¥1,292.61, primarily due to an increase in government subsidies received[10] - The net cash flow from financing activities was ¥3,879.44, a 373.68% increase attributed to increased long-term borrowings[10] - The company's trading financial assets increased to ¥183,535,545.27 from ¥112,929,191.52[19] - The accounts receivable as of March 31, 2022, is ¥248,726,285.56, slightly up from ¥247,350,230.42[19] - The inventory value is reported at ¥181,154,620.99, down from ¥187,132,866.18[19] Strategic Developments - The company has not reported any new strategies or significant market expansions in the current quarter[19]